Lowering Your GLP-1 Dose

Most GLP-1 conversations are about going up. Titration schedules, week-four increases, the path to the maximum dose. The reverse conversation — stepping down — is less written about but increasingly common as more users settle into long-term maintenance.

Lowering the dose is not the same as stopping. It is a planned reduction from your year-one or maximum dose to a smaller maintenance dose. The reasons vary: cost, residual side effects, a desire to test the lowest effective dose, or simply finding the dose that holds the loss without overshooting. Done thoughtfully, it can be a sustainable long-term arrangement.

This guide walks through the typical reasons people lower their dose, what the data and clinical experience say about the trade-offs, and how to think about the practical mechanics with your prescriber.

What the research shows

The pivotal trials studied fixed maximum doses — semaglutide 2.4 mg and tirzepatide 5/10/15 mg — and most long-term data comes from users who stayed at those doses. SURMOUNT-1 included a useful comparison: users on tirzepatide 5 mg lost a mean of 15%, on 10 mg around 19.5%, and on 15 mg around 20.9% at week 72. The dose-response relationship is real but not linear — the gap between 10 and 15 mg is smaller than the gap between 5 and 10 mg.

For semaglutide, the dose-response is similar in shape. STEP 1 used 2.4 mg as the active arm. Lower-dose semaglutide for diabetes (Ozempic at 0.5, 1.0, and 2.0 mg) also produces meaningful weight loss, just less than 2.4 mg on average. The practical implication: a lower maintenance dose is biologically reasonable. The medication still works at lower doses, just with proportionally less appetite suppression.

What is less well studied in clinical trials is whether a step-down maintenance dose — say, from 2.4 mg to 1.0 mg after reaching plateau — holds the loss as well as continuing at the maximum dose. Clinical experience suggests it often does for users who have already locked in their habits, but the data is observational rather than randomized. Some users hold loss adequately on a lower dose; some experience gradual regain and need to return to the higher dose.

What this looks like day-to-day

The most common reason for lowering the dose is cost. The list price of brand-name semaglutide and tirzepatide is high, insurance coverage is inconsistent, and a step-down from 2.4 mg to 1.0 mg can change the monthly out-of-pocket meaningfully if you are paying through a pharmacy. For some users, the difference between the maximum dose and a maintenance dose is the difference between continuing and stopping.

The second common reason is side effects. Most users tolerate the maximum dose by month 12, but a subset live with low-grade GI symptoms — occasional nausea after large meals, constipation, reflux — that improve at lower doses. If those symptoms have been background noise for a year, a step-down trial is a reasonable way to see whether they were dose-driven.

The third reason is dialing in the lowest effective dose. Some users want to know the floor — the smallest dose that holds their loss — and the only way to find out is to step down and observe. This is usually done in small increments (one dose level at a time), with a few weeks at each step to see how appetite and weight respond before deciding to step down again or hold.

Mechanically, stepping down looks like reverse titration. For semaglutide, the dose levels are 0.25, 0.5, 1.0, 1.7, and 2.4 mg. Most step-downs move one level at a time. For tirzepatide, the dose levels are 2.5, 5, 7.5, 10, 12.5, and 15 mg. The same one-level-at-a-time principle applies. Some users need to back up if the lower dose lets too much appetite return; that is normal and not a failure.

Common questions

Keep exploring

Browse all GLP-1 guides.